The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme

Bain, Jerald; Rachlis, Val; Robert, E A; Khait, Zoya

doi:10.1016/s0010-7824(80)80015-1

Cited by 18 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the daily oral administration of methyltestosterone and medroxyprogesterone acetate have already been tried, but with only partial success. (Bain et al 1979). Other esters of testosterone, with higher oral potency, should be tested before ruling out that possibility.…”

Section: Discussionmentioning

confidence: 99%

Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg)

et al. 1981

View full text Add to dashboard Cite

The combination of an initial injection of 1000 mg of depot medroxyprogesterone acetate and 500 mg of testosterone enanthate, followed by monthly administration of 150 mg and 500 mg of the same drugs, was tested in 10 healthy males aged 28 through 39, with pre-treatment sperm counts of 50 x 10(6)/ml or more. Eight of the subjects achieved azoospermia, and the sperm counts of the other two declined 0.09 ad 5 million/ml. This last subject was highly refractory to treatment as his sperm density recovered to 27 million sperm/ml at the 6th month of continuous therapy. FSH was severely depressed during the entire treatment period. LH fell to 30--40% of normal values in the first two months and then showed a slow recovery during maintenance treatment. Testosterone measured one month after each injection was between 10 and 30% of pre-treatment values. Three of the subjects had increased libido and potency, none had decreased sexual drive or potency. All subjects gained weight with the average gain being 6 kg. The increase in the dose of testosterone enanthate to 500 mg/ng did not improve the results as compared to previous trials using lower doses of TE.

show abstract

Section: Discussionmentioning

confidence: 99%

Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg)

et al. 1981

View full text Add to dashboard Cite

show abstract

“…More recently, Bain et al (1980), obtained sup¬ pression of spermatogenesis with a high dose of gestagen, medroxy-progesterone 20 mg daily, but did not, as Heller did, obtain azoospermia. This is probably because Bain et al (1980) combined the gestagen with a daily oral dose of 10-20 mg methyl testosterone.…”

Section: Proteinsmentioning

confidence: 96%

“…The side effects reported in male contraceptive studies are decreased libido (Heller et al 1959; Skoglund & Paulsen 1973), weight gain (Frick et al 1977a,b;Alvarez-Sanchez et al 1977;Coutinho & Melo 1973Brenner et al 1975), and gyne-comastia (Heller et al 1959;Bain et al 1980). Inno studies have psychological side effects been re¬ ported, which in our studies lead to discontinuation in 15% (6 of 39 men) of the volunteers (Table 14).…”

Section: Proteinsmentioning

confidence: 99%

Evaluation of Steroids as COntraceptives in Men

Foegh¹

1983

Acta Endocrinologica

View full text Add to dashboard Cite

At the time this study was initiated in 1974, the most attractive approach to male contraception in view of the success with the female oral contraceptive was by use of steroids, since coitus interruptus, sperm-barrier methods and vasectomy have major drawbacks in terms of either psychological stress, inconvenience or irreversibility. Of particular concern is the high failure rate of the first two methods. Moreover, contemporary society requires a male contraceptive, like that for the female, not only to be effective, but also safe, easily used and, in contrast to vasectomy, readily reversible. An attractive feature of a reversible oral contraceptive is the potential for minimizing potential side effects due to alternation of contraception between partners.However, an overriding concern in developing an oral contraceptive for men, who are not as motivated as strongly as women, is a wide margin of safety. Furthermore, in women, the risk of contraception is compared to the risk of pregnancy and abortion; while in men, the risk has to be

show abstract

“…In the Caucasian population, the oral and the depot injectable MPA formulations were administered in combination with oral or injectable T preparations, respectively. Oral MPA was given in combination with oral T, such as methyl‐T, or with percutaneous dihydrotestosterone (DHT; Tables 1a and 2; Bain et al, 1980; Guerin and Rollet, 1988; Soufir et al, 1983). Depot medroxyprogesterone acetate (DMPA) injected every 4–6 weeks was given in combination with TE (Alvarez‐Sanchez et al, 1977; Brenner et al, 1977; Frick et al, 1977a; Melo and Coutinho, 1977; Alvarez‐Sanchez et al, 1979; Faundes et al, 1981; Frick et al, 1982; Wu and Aitken, 1989; Pangkahila et al, 1991; WHO 1993); testosterone propionate (TP; Frick et al, 1977a); testosterone cypionate (TC; Paulsen et al, 1980; Lee et al, 1979); 19‐nortestosterone (19‐NT); or T pellets (Knuth et al, 1989; Handelsman et al, 1996; WHO 1993; (Tables 1a and 3).…”

Section: Studies With Androgen‐progestin Combinationsmentioning

confidence: 99%

A Review of Androgen‐Progestin Regimens for Male Contraception

2003

Journal of Andrology

View full text Add to dashboard Cite

The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme

Cited by 18 publications

References 6 publications

Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg)

Sperm suppression with monthly injections of medroxyprogesterone acetate combined with testosterone enanthate at a high dose (500 mg)

Evaluation of Steroids as COntraceptives in Men

A Review of Androgen‐Progestin Regimens for Male Contraception

Contact Info

Product

Resources

About